From Arsenic in Antifreeze to a Single Pill

Key Takeaways

• EMA approved acoziborole, a single-dose oral cure with 96% efficacy.
• DNDi has delivered 14 treatments for neglected diseases since 2003.
• Sleeping sickness cases dropped 98% from 1998 to 2024.
• New drug eliminates need for toxic arsenic injections.
• Implementation partners are critical to reach remote African villages.

Pulse Analysis

Human African trypanosomiasis, commonly called sleeping sickness, has long haunted sub‑Saharan Africa. Transmitted by the tsetse fly, the disease progresses from fever and headache to neurological invasion, seizures and almost certain death without therapy. For decades the only option was melarsoprol, an arsenic‑based compound dissolved in propylene glycol—essentially antifreeze—that killed the parasite but also caused severe encephalopathy in up to 15 % of patients, with a mortality rate of roughly one in twenty. The toxicity and need for intravenous administration made large‑scale treatment logistically daunting and ethically fraught.

The breakthrough arrived with acoziborole, a three‑tablet, single‑dose regimen that achieved 96 % cure rates in an 18‑month follow‑up. Developed through a partnership between the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, the drug bypasses injections, eliminates arsenic exposure and can be administered in community settings. The European Medicines Agency’s positive opinion in early 2024 cleared the path for rapid rollout across the 36 endemic countries. Since DNDi’s first oral therapy, fexinidazole, in 2018, reported cases have plummeted from nearly 40,000 in 1998 to just 546 this year, underscoring how targeted R&D can transform public‑health outcomes.

The remaining hurdle is delivery: ensuring acoziborole reaches patients in remote villages where health infrastructure is sparse. Implementation catalysts such as Resolve to Save Lives partner with national programs, training community health workers, managing supply chains and monitoring adherence to close the final mile. Success will demonstrate a scalable model for other neglected tropical diseases, proving that mission‑driven collaborations, pragmatic data use and focused funding can overcome market failures and save millions of lives.